Search

The article discusses whether two former members of the U.S. National Highway Traffic Safety Administration (NHTSA) have helped Toyota Motor Corp. close four NHTSA investigations into reports of unintended acceleration by Toyota automobiles since 2004. Toyota claims neither Christopher Tinto nor Christopher Santucci did anything improper. INSET: U.S. REGULATORS HIRED BY TOYOTA HAVE HELPED DEFLECT....

The article focuses on the pharmaceutical company Novartis and the patent expiration of its heart medication Diovan in September of 2012. Topics include Indian pharmaceutical company Ranbaxy Laboratories' exclusive right to create Diovan in India and U.S. regulators decision to prevent the distribution of Diovan in India due to concerns over unsafe working conditions in Ranbaxy factories.

The article focuses on biosimilar drugs, which are generic versions of biologics, the name for medicine produced using the body's own cells rather than through chemical reactions in a laboratory. Topics include the loss of patent protections for biologics between 2013 and 2019 and why biosimilar drugs may not contain all of the ingredients of biologics.

The article presents information on efforts by European regulators to lobby drugmakers to increase regulation of the sale of compounds used in lethal injections. Topics include law and legislation related to lethal injection and capital punishment in the U.S.; the pharmaceutical industry in Europe which supplies U.S. states with prescription drugs; and export controls of drugs shipped from Europe to U.S. prisons.

The article discusses the apology made by Akio Toyoda, Toyota Motor Corp. president, regarding the growing recall crisis the company experienced during his first scheduled public appearance in the U.S. The company's production of its best-selling models were stopped due to the said recall crisis. The U.S. Transportation Department has conducted investigation of brake failures in the Prius. Due to the complaints the company has received, it changed its brake software at the end of January.

The article reports on the reputation of Toyota Motor Corp. after the product recall of Toyota vehicles in the U.S. Casesa Shapiro Group LLC senior adviser Maryann Keller states that the long term quality reputation of Toyota is finished because the incident of product recall is enough to keep people out from stores. It mentions that Toyota decided to halt production and sale of eight vehicle models after the recall which may promote a total lose of 20,000 vehicles sales a week.